MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
By Gift Briton Global efforts for a Rift Valley fever (RVF) vaccine accelerate as South Africa’s Afrigen Biologics begins local development of mRNA vaccine.With no vaccine approved for human use yet, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback